Piyush Goyal Criticises Attempts to Secure Pharma Patents Through Minor Innovations

Commerce and Industry Minister Piyush Goyal recently criticised some companies for seeking pharmaceutical patents through minor innovations. He argued that such practices could limit access to affordable medicines for millions. "Just for the super-natural profits of a few companies and their shareholders, the world has to suffer and is deprived of quality and equitable healthcare," he stated.

Representative image

Goyal highlighted frequent requests from pharmaceutical firms to allow incremental changes to patents, granting them extended protection. This practice, known as evergreening, involves making minor modifications to existing drugs to secure new patents. He expressed concern that this benefits only a few companies at the expense of global healthcare access.

Patent Laws and Public Interest

India's patent laws, specifically Section 3d of the Indian Patents Act, 1970, restrict patents for known drugs unless new claims show improved efficacy. Section 3b prevents patents for products against public interest without enhanced efficacy over existing ones. Some multinational firms have urged India to amend these laws, but such proposals have faced strong opposition.

Evergreening allows patent holders to extend their monopoly by making minor changes like new mixtures or formulations when patents near expiration. A new patent form could grant a company a 20-year monopoly on a drug. This strategy is often criticised for prioritising profits over public health needs.

Healthcare Access and Sustainable Development

Goyal emphasised that access to quality healthcare is vital for sustainable development. He shared India's progress in improving healthcare access for all citizens. Ensuring affordable medicines is crucial in this journey, aligning with broader goals of equitable healthcare distribution.

The minister's remarks underscore the ongoing debate over balancing innovation incentives with public health interests. As India navigates these challenges, maintaining strict patent regulations remains a key focus to ensure medicines remain accessible and affordable.

Goyal's comments reflect India's commitment to safeguarding public health by resisting pressures to dilute patent laws. By prioritising patient needs over corporate profits, India aims to foster an environment where healthcare advancements benefit everyone.